Stock PHIO PHIO PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
0.7045 USD -8.51% Intraday chart for Phio Pharmaceuticals Corp. -14.05% -7.30%
May. 09 Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
GL
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
AQ
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
AQ
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762
CI
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology
CI
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
AQ
National Spotlight Features Phio’s Innovative RNAi Technology Platform
AQ
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
GL
North American Morning Briefing : Stocks Seen -2-
DJ
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
AQ
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
CI
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
AQ
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research
CI
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders
MT
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
AQ
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
CI
HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. News Phio Pharmaceuticals Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW